恒瑞医药：HER2 ADC拿下第10项突破治疗

医药笔记02-04

▎Armstrong2026年2月3日，恒瑞医药HER2 ADC新药SHR-A1811一线治疗HER2激活突变NSCLC拟纳入突破治疗药物程序。这也是SHR-A1811拿下的第10项突破治疗，此前的9个适应症分别为HER2阳性乳腺癌、HER2低表达乳腺癌、铂耐药HER激活突变NSCLC、既往经奥沙利铂/氟尿嘧啶和伊立替康治疗失败的HER2阳性结直肠癌、既往至少一线抗HER2治疗失败的HER2阳性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608335923?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-04 09:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2608335923","market":"hk","top_or_hot":-1,"title":"恒瑞医药：HER2 ADC拿下第10项突破治疗","media":"医药笔记","content":"<div>\n<p>▎Armstrong2026年2月3日，恒瑞医药HER2 ADC新药SHR-A1811一线治疗HER2激活突变NSCLC拟纳入突破治疗药物程序。这也是SHR-A1811拿下的第10项突破治疗，此前的9个适应症分别为HER2阳性乳腺癌、HER2低表达乳腺癌、铂耐药HER激活突变NSCLC、既往经奥沙利铂/氟尿嘧啶和伊立替康治疗失败的HER2阳性结直肠癌、既往至少一线抗HER2治疗失败的HER2阳性...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204093203a6d07e08&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药：HER2 ADC拿下第10项突破治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药：HER2 ADC拿下第10项突破治疗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-04 09:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204093203a6d07e08&s=b><strong>医药笔记</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>▎Armstrong2026年2月3日，恒瑞医药HER2 ADC新药SHR-A1811一线治疗HER2激活突变NSCLC拟纳入突破治疗药物程序。这也是SHR-A1811拿下的第10项突破治疗，此前的9个适应症分别为HER2阳性乳腺癌、HER2低表达乳腺癌、铂耐药HER激活突变NSCLC、既往经奥沙利铂/氟尿嘧啶和伊立替康治疗失败的HER2阳性结直肠癌、既往至少一线抗HER2治疗失败的HER2阳性...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204093203a6d07e08&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2543165471.USD","symbol_name":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204093203a6d07e08&s=b","article_id":"2608335923","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204093203a6d07e08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608335923","pubTimestamp":1770167012,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"▎Armstrong2026年2月3日，恒瑞医药HER2 ADC新药SHR-A1811一线治疗HER2激活突变NSCLC拟纳入突破治疗药物程序。总结恒瑞医药将ADC作为其布局重点，并积极开发下一代的新毒素ADC，以及第三代的双毒素ADC。除此之外，恒瑞医药扩展布局到DAC、APC、AOC等领域。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","01276":"恒瑞医药","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK1191":"制药","LU0359201612.USD":"贝莱德中国基金A2"},"translate_title":"Hengrui Medicine: HER2 ADC wins the 10th breakthrough treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1.5},"content_text":"▎Armstrong2026年2月3日，恒瑞医药HER2 ADC新药SHR-A1811一线治疗HER2激活突变NSCLC拟纳入突破治疗药物程序。这也是SHR-A1811拿下的第10项突破治疗，此前的9个适应症分别为HER2阳性乳腺癌、HER2低表达乳腺癌、铂耐药HER激活突变NSCLC、既往经奥沙利铂/氟尿嘧啶和伊立替康治疗失败的HER2阳性结直肠癌、既往至少一线抗HER2治疗失败的HER2阳性胃癌、既往接受过一种或一种以上治疗方案的HER2阳性不可切除或转移性胆道癌、HER2表达的铂耐药复发上皮性卵巢癌/输卵管癌或原发性腹膜癌、既往接受含铂化疗及免疫检查点抑制剂治疗失败的HER2表达（IHC≥1+）的复发或转移性宫颈癌、联合阿得贝利单抗一线治疗PD-L1阳性（CPS≥1）三阴性乳腺癌。总结恒瑞医药将ADC作为其布局重点，并积极开发下一代的新毒素ADC，以及第三代的双毒素ADC。除此之外，恒瑞医药扩展布局到DAC（抗体偶联降解剂）、APC（抗体偶联多肽）、AOC（抗体偶联小核酸）等领域。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608335923","isCrawlerRequest":true}